Barclays Rates Sotera Health (SHC) buy, $19 Price Target
Barclays' analyst Luke Sergott maintains a buy rating on SHC, setting a price target of $19, a 10.82% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Sotera Health Company ($SHC) "buy" with a $19 price target on June 24, 2026.
Since the rating, $SHC is up 6.3% after 1 week, up 4.0% after 1 month and up 7.2% to date (from the $16.69 close on Jun 24, 2026).
SHC
Sotera Health Company
Key Points
- Barclays' analyst Luke Sergott reiterated a buy rating on SHC with a price target of $19 as of June 24, 2026.
- Barclays's $19 price target implies 10.82% upside from Sotera Health Company's ($SHC) current $17.14 share price.
- Shares of SHC traded near $16.30 on Wednesday, June 24, 2026.
- Darsana Capital Partners holds 26 million shares of SHC, while BlackRock increased its stake by 2,770,086 shares.
Get $SHC trade alerts by text
We text you when insiders, Congress or big funds trade $SHC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sotera Health Company alert may contain errors. Disclosures
On June 24, 2026, Barclays' analyst Luke Sergott reiterated a buy rating on SHC, setting a price target of $19. This announcement comes as part of Barclays' ongoing coverage of the company.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in SHC
Darsana Capital Partners maintained its stake in SHC with 26 million shares valued at approximately $372.84 million. Sessa Capital IM, L.P. increased its holdings by 2.5 million shares, bringing its total to 23.05 million shares worth about $330.54 million, marking a 12.2% increase. Sculptor Capital LP also added 717,728 shares, ending with 21.72 million shares valued at $311.43 million, a 3.4% boost. BlackRock, Inc. increased its investment by 2,770,086 shares, now holding 20.85 million shares worth roughly $298.98 million, a 15.3% increase. Meanwhile, Warburg Pincus LLC reduced its stake by 15 million shares, closing with 19.1 million shares, a 44% decrease.
Sotera Health Company Stock Down 8.5%
Shares of SHC traded near $16.30 on Wednesday, June 24, 2026. While specific financial metrics such as market cap, P/E ratio, and beta were not disclosed, the stock's recent activity reflects ongoing interest and adjustments by institutional investors.
$SHC price target
Sotera Health Company daily closes and this analyst's $19 target. Not advice.
Insider Buying and Selling at Sotera Health Company
On May 26, 2026, Alton Shader, SHC's Chief Executive Officer, made multiple purchases totaling 681,390 shares. Additionally, on May 22, 2026, insiders James Neary, Vincent Petrella, and David Wheadon each bought 14,970 shares. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained its buy rating on SHC with a $19 price target. Earlier, on June 5, 2026, Goldman Sachs initiated coverage with a buy rating and a $20 target. Piper Sandler reiterated a buy rating with a $22 target on May 6, 2026. The analyst consensus remains positive, with several firms maintaining buy ratings and targets ranging from $19 to $24.
Bottom Line
Barclays' reaffirmation of a buy rating on SHC with a $19 target highlights continued confidence in the company's prospects. Institutional activity shows mixed adjustments, with some funds increasing their stakes while others reduce theirs. Insider buying suggests optimism among SHC's leadership. Investors should note that these ratings and transactions reflect past decisions and may not indicate current positions.
Related Filing Alerts
Source: Barclays's rating change on $SHC (Jun 24, 2026). Written by software, not financial advice. How we make alerts